Based on application type, the global Pegfilgrastim Biosimilar Market is segmented as: Chemotherapy Treatment Myelosuppressive
Chemotherapy Treatment Induction or Consolidation Chemotherapy Treatment Transplantation Bone Marrow Transplantation Peripheral Blood Progenitor Cell Transplantation Based on distribution channels, the global Pegfilgrastim Biosimilar Market is segmented as: Hospital pharmacies Retail pharmacies Mail-Order pharmacies Based on geography, the global Pegfilgrastim Biosimilar Market is segmented as: North America Latin America Europe CIS & Russia Japan APEJ Middle East & Africa Pegfilgrastim Biosimilar Market: Overview Increasing incidences of cancer are leading to increased chemotherapy procedures.
Because of the well reported incidence of gross-hematuria and hemorrhagic cystitis in patients undergoing conditioning for allogeneic BMT/SCT, these patients are routinely prophylactically treated with continuous bladder irrigation (CBI), 2-mercaptoethanesulfonic acid (mesna), and hyperhydration during their myelosuppressive
In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive
chemotherapy as compared to those who received chemotherapy alone.
Rolontisis a long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive
In this study, we evaluated the efficacy and safety of prophylaxis with original and biosimilar filgrastims, which are the most commonly used recombinant G-CSFs, in children receiving myelosuppressive
In the presence of splenomegaly, long term neutropenia and fever in a patient with a >10 years history of RA and after exclusion of hematological disease or infection by a myelosuppressive
agent the diagnosis of FS and bacterial infection by an unidentified agent was admitted.
The company is pursuing approval of the product to decrease the incidence of infection, as manifested by febrile neutropenia (low white blood cell count with a fever), in patients with non-myeloid malignancies receiving myelosuppressive
anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
ROLONTIS is being evaluated as a novel therapy for the management of chemotherapy-induced neutropenia in patients undergoing myelosuppressive
We concluded that aqueous wheat extract at a dose of 100mg/kg and 400mg/kg are effective in reducing the myelosuppressive
effect andoxidative stress caused by carboplatin.
GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with nonmyeloid malignancies receiving myelosuppressive
anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Neutropenia is a major side effect of myelosuppressive
chemotherapies including induction therapy and leaves patients at high risk of serious, often life-threatening infections.
Other causes of anemia include concomitant inflammation or infection, cancer, hemolysis, hemoglobinopathies, severe hyperparathyroidism, aluminum intoxication, vitamin B12 and folate deficiencies, inadequate dialysis, myelosuppressive
agents, myelodysplasia, pure red cell aplasia, and thyroid dysfunction (9,12-17).